Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk Ventilation 69% Combined death/ventilat.. 47% Hospitalization time 0% Ct<30 17% c19mp.com Wong et al. Molnupiravir for COVID-19 LATE TREATMENT Favors molnupiravir Favors control
Wong, 10,512 patient molnupiravir late treatment PSM study: 45% lower mortality [p<0.0001], 69% lower ventilation [p=0.0006], 47% lower combined mortality/ICU admission [p<0.0001], and no change in hospitalization [p=0.86] https://c19p.org/wong3
copied to clipboard
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
Wong et al., medRxiv, doi:10.1101/2022.05.19.22275291 (Preprint)
20 May 2022    Source   PDF   Share   Tweet
PSM retrospective 40,776 hospitalized patients in Hong Kong, showing lower mortality and mechanical ventilation with molnupiravir treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
risk of death, 45.0% lower, HR 0.55, p < 0.001, treatment 2,116, control 8,396, propensity score matching.
risk of mechanical ventilation, 69.0% lower, HR 0.31, p < 0.001, treatment 2,116, control 8,396, propensity score matching.
combined death/ventilation/ICU, 47.0% lower, HR 0.53, p < 0.001, treatment 2,116, control 8,396, propensity score matching.
hospitalization time, 0.5% lower, relative time 1.00, p = 0.86, treatment 2,116, control 8,396, propensity score matching.
Ct<30, 17.4% lower, HR 0.83, p = 0.003, treatment 2,115, control 8,396, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 5/20/2022, retrospective, China, preprint, 6 authors, study period 26 February, 2022 - 26 April, 2022.
Contact: carlosho@hku.hk, bcowling@hku.hk.
All Studies   All Outcomes
This PaperMolnupiravirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit